1. In vitro activities of 8 antifungal drugs against 126 clinical and environmental Exophiala isolates.
- Author
-
Najafzadeh MJ, Dolatabadi S, Vicente VA, de Hoog GS, and Meis JF
- Subjects
- Animals, Antifungal Agents classification, Antifungal Agents therapeutic use, Exophiala classification, Exophiala genetics, Humans, Microbial Sensitivity Tests, Phaeohyphomycosis drug therapy, Antifungal Agents pharmacology, Environmental Microbiology, Exophiala drug effects, Phaeohyphomycosis microbiology
- Abstract
Background: Exophiala is the main genus of black fungi comprising numerous opportunistic species. Data on antifungal susceptibility of Exophiala isolates are limited, while infections are potentially fatal., Materials and Methods: In vitro activities of eight antifungal drugs (AMB, five azoles, two echinocandins) against 126 clinical (n = 76) and environmental (n = 47) isolates from around the world were investigated. E. oligosperma (n = 58), E. spinifera (n = 33), E. jeanselmei (n = 14) and E. xenobiotica (n = 21) were included in our dataset., Results: The resulting MIC
90 s of all strains were as follows, in increasing order: posaconazole 0.063 μg/ml, itraconazole 0.125 μg/ml, voriconazole and amphotericin B 1 μg/ml, isavuconazole 2 μg/ml, micafungin and caspofungin 4 μg/ml, and fluconazole 64 μg/ml. Posaconazole, itraconazole and micafungin were the drugs with the best overall activity against Exophiala species. Fluconazole could not be considered as a treatment choice. No significant difference could be found among antifungal drug activities between these four species, neither in clinical nor in environmental isolates., Conclusion: Antifungal susceptibility data for Exophiala spp. are crucial to improve the management of this occasionally fatal infection and the outcome of its treatment., (© 2021 Wiley-VCH GmbH.)- Published
- 2021
- Full Text
- View/download PDF